Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
1.83
-0.16 (-8.04%)
Market open: Aug 12, 2026, 3:34 PM EDT
1.94
0.00 (0.00%)
Previous after-hours: Aug 11, 2026, 7:34 PM EDT
Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company that develops novel therapies for life-threatening immune and thrombotic conditions. The company is developing Tecarfarin, an oral vitamin K antagonist that is in Phase 3 clinical trial designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, and atrial fibrillation; CAD-1005, a first-in-class 12-LOX inhibitor for the treatment of heparin-induced thrombocytopenia, a deadly immune-mediated thrombotic disorder that has completed Phase 2 clinical trial; and Frunexian, a parenteral clinical-stage factor XIa inhibitor designed for use in acute hospital settings that has completed Phase 1 clinical trial. It has a collaboration agreement with Abbott Global Enterprises Limited to evaluate the efficacy and safety of Tecarfarin in patients with a left-ventricular assist device. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
| Name | Position |
|---|---|
| Mr. Jeffrey Cole | Chief Operating Officer |
| Mr. John P. Sharp CPA | Interim CFO & Principal Accounting Officer |
| Mr. Quang X. Pham | Chairman & CEO |
| Date | Type | Document |
|---|---|---|
| 2026-08-03 | DEFA14A | ea0298910-03.htm |
| 2026-08-03 | DEF 14A | ea0298910-02.htm |
| 2026-07-23 | PRE 14A | ea0298910-01.htm |
| 2026-07-21 | 8-K | ea0298669-8k_cadrenal.htm |
| 2026-07-17 | 8-K | ea0298082-8k_cadrenal.htm |
| 2026-07-15 | D | |
| 2026-07-13 | S-3 | ea0297376-s3_cadrenal.htm |
| 2026-07-10 | 8-K | ea0297603-8k_cadrenal.htm |
| 2026-07-01 | 8-K | ea0296666-8k_cadrenal.htm |
| 2026-06-29 | 8-K | ea0296328-8k_cadrenal.htm |